Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure

The role of ribavirin (RBV) in the era of direct-acting antivirals (DAA) is not clear, and DAA studies have been largely genotype- and regimen-specific. Using data from the Chronic Hepatitis Cohort Study, we evaluated the role of RBV and increased DAA treatment duration among patients with chronic h...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Viral Hepat
Main Authors: Lu, Mei, Wu, Kuan-Han, Li, Jia, Moorman, Anne C., Spradling, Philip R., Teshale, Eyasu H., Boscarino, Joseph A., Daida, Yihe G., Schmidt, Mark A., Rupp, Loralee B., Zhang, Talan, Trudeau, Sheri, Gordon, Stuart C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6764853/
https://ncbi.nlm.nih.gov/pubmed/31197910
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jvh.13162
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados